Allarity Therapeutics, Inc. (ALLR), a clinical-stage biopharma focused on personalized cancer treatments, announced it has closed a $20 million non-convertible debt financing with Streeterville Capital to accelerate the development of its lead candidate, Stenoparib, a dual PARP and WNT pathway inhibitor, toward FDA approval and commercialization.
The financing, structured as two promissory notes, is expected to extend Allarity's cash runway into mid-2028. Proceeds will support completion of the ongoing Phase 2 ovarian cancer trial, preparation for pivotal development, and advancement of the company's Drug response Predictor (DRP) companion diagnostic platform. CEO Thomas Jensen stated the capital positions Allarity to complete Phase 2 enrolment, prepare for an FDA meeting, and advance its companion diagnostic strategy.
Stenoparib/2X-121 has shown durable clinical benefit in heavily pre-treated ovarian cancer patients, with some remaining on therapy for more than 30 months. The drug's dual mechanism- blocking PARP and WNT signaling - offers potential across multiple cancer types, including ovarian, small cell lung, and colorectal cancers. Allarity holds exclusive global rights for development and commercialization.
ALLR has traded between $0.61 and $2.35 over the past year. The shares surged following the announcement, closing Friday's (March 6,2026) trading session up 21%. During overnight trading session, the stock is up 3.23% to $1.28.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.